How to Account for Patents: Capitalization, Amortization, and Impairment

To account for patents under US GAAP, you capitalize the qualifying costs of acquiring or securing the patent as an intangible asset, amortize that cost on a straight-line basis over the shorter of its 20-year legal life or its estimated economic life, and test it for impairment whenever an event suggests its value has fallen below its carrying amount. Almost everything else in patent accounting flows from those three steps. The details that trip people up are which costs qualify for capitalization in the first place, how to pick a useful life that isn’t just the legal maximum, and how to handle the write-down when a patent stops earning its keep.

What Costs Go on the Balance Sheet

The capitalization question splits cleanly in two depending on whether you built the patent yourself or bought it.

Internally Developed Patents

If your company invented the technology, ASC 730 requires you to expense research and development costs as incurred.1Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive Scientist salaries, lab costs, prototype materials, and failed experiments all hit the income statement in the period they occur. The reasoning is that success is too uncertain to justify recording an asset before you actually have one.

Only a narrow set of costs incurred once the patent becomes legally viable can be capitalized: the direct legal and filing costs needed to secure the patent, which typically means attorney fees for drafting and prosecuting the application and the government filing and registration fees paid to the USPTO. Because these represent a small fraction of what was actually spent bringing the invention into existence, internally developed patents tend to appear on balance sheets at surprisingly low values.

Costs of successfully defending a patent against infringement can also be added to the asset’s carrying value, but only when the defense succeeds and demonstrably increases the patent’s economic value. If the defense fails, those legal costs are expensed in the current period. Companies sometimes want to capitalize defense costs while litigation is still ongoing, and this is one of the areas where judgment calls get contentious.

Purchased Patents

A patent bought from a third party is simpler. The entire purchase price is capitalized, along with any costs necessary to complete the transaction and prepare the asset for use: appraisal fees, broker commissions, and transfer taxes. The result is a cost basis that reflects the full economic sacrifice required to obtain the asset.

When a patent comes in as part of a business combination, the total acquisition price is allocated across all identifiable assets and liabilities at their fair values, and the patent receives its own fair value allocation. That allocated fair value becomes the capitalized cost basis going forward and drives every subsequent amortization and impairment calculation.

How to Amortize the Capitalized Cost

Once the patent is on the balance sheet, its capitalized cost is systematically allocated to expense over the period it generates economic value, the same way depreciation works for physical assets.

The legal ceiling for utility and plant patents is 20 years from the filing date.2United States Patent and Trademark Office. MPEP 2701 – Patent Term But the amortization period is always the shorter of the legal life or the estimated economic life. In technology-driven industries, a patent’s economic usefulness might last only five to seven years before newer technology leapfrogs the underlying invention. Management has to weigh the rate of technological change, competitive dynamics, expected demand shifts, and the stability of the regulatory environment when picking a useful life.

Straight-line amortization is the default. Divide the capitalized cost by the estimated useful life in years, and that’s the annual expense. A patent capitalized at $50,000 with a 10-year useful life produces $5,000 of amortization expense each year. Units-of-production or accelerated methods are permitted only if they more accurately reflect how the economic benefits are actually consumed, and justifying an alternative pattern requires significant evidence, so most companies stick with straight-line.

If circumstances change and the remaining useful life needs to be revised, the adjustment is prospective. Spread the remaining carrying value over the new, shorter remaining life. There’s no going back to restate prior periods.

When to Test for Impairment

Amortization handles the expected, gradual decline in value. Impairment testing addresses the unexpected drop: a competitor launches a superior product, a court ruling narrows the patent’s scope, or a key licensee walks away. Under ASC 360-10, the test is triggered by events rather than performed on a fixed schedule, and it has two steps.

Step One: The Recoverability Test

Compare the patent’s carrying amount to the sum of undiscounted future cash flows expected from its continued use and eventual disposal. If those undiscounted cash flows exceed the carrying amount, the patent passes and no impairment is recorded. This first step is intentionally a low bar, designed to screen out cases where a full fair value analysis isn’t warranted.

Step Two: Measuring the Loss

If the patent fails step one, move to fair value. The impairment loss equals the amount by which carrying value exceeds fair value. Fair value is typically determined using a discounted cash flow analysis, with projected future cash flows discounted at a rate that reflects the time value of money and the specific risks of the patent. The carrying value is then written down to fair value, and the loss hits the income statement in the period recognized.

One rule that catches people off guard: US GAAP does not permit reversal of a previously recognized impairment loss, even if the patent’s value later recovers. The written-down amount becomes the new cost basis, and it’s amortized over the remaining useful life from there. The adjustment is permanent and one-way.

Maintenance Fees and Abandonment

Keeping a patent in force requires periodic maintenance fee payments to the USPTO at 3.5, 7.5, and 11.5 years after grant.3USPTO – United States Patent and Trademark Office. USPTO Fee Schedule These fees are expensed as incurred rather than capitalized. They preserve the existing legal right but don’t create new economic value or extend the useful life beyond what was already estimated.

When a company decides a patent is no longer worth maintaining, it stops paying the fees and the patent lapses. Under ASC 360-10, a decision to abandon a patent before the end of its previously estimated useful life is itself an indicator of impairment. Test for recoverability, and if it fails, write the carrying value down to fair value, which for an abandoned patent is typically zero or close to it. The remaining net book value is recognized as a loss on the income statement. The patent remains classified as held and used until it actually ceases to be used, at which point the carrying amount should equal its salvage value, if any.

Where Book and Tax Treatment Diverge

Financial reporting and tax accounting for patents follow different rules, and the gap between them creates deferred tax items you need to track.

A patent acquired from a third party qualifies as a Section 197 intangible under the Internal Revenue Code and must be amortized over a fixed 15-year period for tax purposes, regardless of its actual economic or legal life. If book useful life is 10 years and tax life is 15 years, the mismatch creates a temporary difference that shows up as a deferred tax liability or asset. Self-created patents generally do not qualify as Section 197 intangibles; the statute excludes intangibles created by the taxpayer unless they were created in connection with acquiring a trade or business.4Office of the Law Revision Counsel. 26 USC 197 – Amortization of Goodwill and Certain Other Intangibles

The tax treatment of internally developed patents shifted for tax years beginning after December 31, 2024. For 2026, domestic research and experimental expenditures are once again immediately deductible under Section 174A of the Internal Revenue Code.5Office of the Law Revision Counsel. 26 U.S. Code 174A – Domestic Research or Experimental Expenditures Companies can also elect to capitalize and amortize these costs over a period of at least 60 months. Foreign research expenditures still require amortization over 15 years.6Internal Revenue Service. Revenue Procedure 2025-28

The practical effect for 2026 is that both GAAP and the tax code treat domestic R&D spending as an immediate expense, eliminating the temporary difference that existed during the 2022–2024 period when TCJA required five-year tax amortization. Companies that were carrying deferred tax assets tied to that difference need to unwind them.

How Patents Appear on the Financial Statements

On the balance sheet, patents sit in the non-current intangible assets section. The reported figure is net book value: original capitalized cost minus accumulated amortization minus any impairment losses. Accumulated amortization works as a contra-asset account, reducing the gross carrying amount the same way accumulated depreciation reduces the value of property and equipment.

The period’s amortization expense appears on the income statement, typically within operating expenses, and any impairment losses are also reported as operating charges in the period recognized.

Footnote disclosures carry the detail analysts actually use. Companies must disclose the gross carrying amount and accumulated amortization for patents, broken out by remaining amortization period, and describe the methods used to determine useful life and calculate amortization. They must also provide a forward-looking estimate of expected amortization expense for each of the next five fiscal years, giving readers a concrete view of how the patent portfolio will affect future profitability.7Financial Accounting Standards Board (FASB). Summary of Statement No. 142 When an impairment loss is recorded, the footnotes should describe the circumstances that triggered the write-down and the method used to determine fair value.